Literature DB >> 32495491

Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.

Matteo Megna1, Angelo Ruggiero1, Adriana Di Guida1, Angela Patrì1, Gabriella Fabbrocini1, Claudio Marasca1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32495491     DOI： 10.1111/dth.13756

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  10 in total

Review 1.  [Systemic treatment of moderate/severe hidradenitis suppurativa].

Authors:  A Pinter; U Mrowietz; T Volz
Journal:  Hautarzt       Date:  2021-06-29       Impact factor: 0.751

2.  An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.

Authors:  Pelin Esme; Aysenur Botsali; Gulsen Akoglu; Ercan Caliskan
Journal:  Skin Appendage Disord       Date:  2022-02-09

3.  A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?

Authors:  Angelo Ruggiero; Matteo Megna; Vincenzo Marino; Luca Costanzo; Gabriella Fabbrocini; Sonia Sofía Ocampo-Garza; Chiara Miano; Lucia Gallo
Journal:  Dermatol Ther       Date:  2022-02-14       Impact factor: 3.858

Review 4.  Skin manifestations in spondyloarthritis.

Authors:  Katharina Meier; Alexandra Schloegl; Denis Poddubnyy; Kamran Ghoreschi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

Review 5.  Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.

Authors:  Angelo Ruggiero; Fabrizio Martora; Vincenzo Picone; Laura Marano; Gabriella Fabbrocini; Claudio Marasca
Journal:  Biomedicines       Date:  2022-02-16

Review 6.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 7.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

8.  Onset of vitiligo in a psoriasis patient on ixekizumab.

Authors:  Claudio Marasca; Luigi Fornaro; Fabrizio Martora; Vincenzo Picone; Gabriella Fabbrocini; Matteo Megna
Journal:  Dermatol Ther       Date:  2021-09-02       Impact factor: 3.858

Review 9.  Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.

Authors:  Zuzanna Świerczewska; Miłosz Lewandowski; Agnieszka Surowiecka; Wioletta Barańska-Rybak
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

10.  Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.

Authors:  Matteo Megna; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Dermatol Ther       Date:  2022-07-11       Impact factor: 3.858
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.